Phase 2 Lymphoma Trial, Recruiting (NCT07451652)

Phase 2 Lymphoma Trial, Recruiting NCT07451652 Sponsor: Hospital Universitario Dr. Jose E. Gonzalez Condition: Lymphoma

Printed from Voxsanity (voxsanity.com.au) — NCT07451652 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lymphoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with a type of blood cancer called diffuse large B-cell lymphoma that has come back or has not responded to previous treatment, and you have already received at least one round of treatment for it
You are considered a suitable candidate to receive a stem cell transplant using your own stem cells
Your general health and ability to carry out daily activities falls within an acceptable range (this is measured using a standard scale — confirm with trial site)
Women who could become pregnant must agree to use a contraceptive method during the trial
Your disease is currently active and measurable according to specific medical guidelines called Lugano criteria (confirm with trial site)
You are willing to take part in this study voluntarily

Who may not be able to join:

You currently have an active infection caused by bacteria, a virus, or a fungus
You have already had a stem cell transplant in the past, either using your own stem cells or those from a donor
You have another type of cancer that is currently active
You have severe organ failure at an end-stage level (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 2 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07451652

Sponsor: Hospital Universitario Dr. Jose E. Gonzalez

Phase: Phase 2

Status: Recruiting

Condition: Lymphoma

More information: https://clinicaltrials.gov/study/NCT07451652

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with a type of blood cancer called diffuse large B-cell lymphoma that has come back or has not responded to previous treatment, and you have already received at least one round of treatment for it
You are considered a suitable candidate to receive a stem cell transplant using your own stem cells
Your general health and ability to carry out daily activities falls within an acceptable range (this is measured using a standard scale — confirm with trial site)
Women who could become pregnant must agree to use a contraceptive method during the trial
Your disease is currently active and measurable according to specific medical guidelines called Lugano criteria (confirm with trial site)
You are willing to take part in this study voluntarily

Who may not be able to join:

You currently have an active infection caused by bacteria, a virus, or a fungus
You have already had a stem cell transplant in the past, either using your own stem cells or those from a donor
You have another type of cancer that is currently active
You have severe organ failure at an end-stage level (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 2 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Hospital Universitario Dr. Jose E. Gonzalez

Registry

ClinicalTrials.gov

Start date

17 March 2026

Est. completion

1 September 2027

Where this trial is recruiting

🇲🇽 Mexico

Primary endpoints

Determine ORR and CR after GemOx plus low-dose Epcoritamab

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov